Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
Abstract Background Patients with lung cancer who are treated with carboplatin-based chemotherapy regimens often experience chemotherapy-induced nausea and vomiting (CINV). However, knowledge on the effect of regimen and cofactors on the risk of CINV is limited. This study aimed to analyze and compa...
Main Authors: | Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Hirotoshi Iihara, Kei Kawada, Takafumi Nakano, Takashi Egawa |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-07802-y |
Similar Items
-
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials
by: Senri Yamamoto, et al.
Published: (2021-07-01) -
Prophylaxis and management of antineoplastic drug induced nausea and vomiting in children with cancer
by: Sidharth Totadri
Published: (2016-10-01) -
Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting
by: Rapoport BL
Published: (2017-02-01) -
Prevention of Nausea and Vomiting in Oncology
by: AV Snegovoi, et al.
Published: (2016-01-01) -
Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
by: Rudolph M. Navari, et al.
Published: (2018-07-01)